Dr. Caleb M. Adler, MD
Psychiatry (Psychiatry Physician)
- Medicare participating
At a glance
- Medical school
- Jefferson Medical College of Thomas Jefferson University (1991)
- Years since graduation
- 35
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 39
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1991Medical school: Jefferson Medical College of Thomas Jefferson University
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Psychiatry Physician primary
OH license 35.075674
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- University of Cincinnati Medical Center, LLC Cincinnati, OH
Medical groups
- University of Cincinnati Physicians Company LLC (1,506 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 39
- Services billed
- 454
- Patients’ average age
- 62
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Payments from drug and device companies
In 2025, 1 companies reported 18 payments worth $11,484 in total to this clinician.
| Janssen Pharmaceuticals, Inc | $11,484 |
|---|
| Compensation for services other than consulting (speaking, faculty) | $9,810 |
|---|---|
| Travel and Lodging | $1,313 |
| Food and Beverage | $361 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Janssen Pharmaceuticals, Inc Mar 11, 2025 | Compensation for services other than consulting (speaking, faculty) SPRAVATO · Neuroscience | $9,810 |
| Janssen Pharmaceuticals, Inc Feb 5, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $550 |
| Janssen Pharmaceuticals, Inc Feb 5, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $452 |
| Janssen Pharmaceuticals, Inc Feb 5, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $144 |
| Janssen Pharmaceuticals, Inc Feb 6, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $66.00 |
| Janssen Pharmaceuticals, Inc Feb 6, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $40.00 |
| Janssen Pharmaceuticals, Inc Feb 8, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $40.00 |
| Janssen Pharmaceuticals, Inc Feb 7, 2025 | Travel and Lodging SPRAVATO · Neuroscience · travel to HOUSTON, TX · in-kind | $21.44 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 9 industry-funded studies in 2025, from 3 companies. The companies reported $163,100 in research payments for these studies, mostly to the institutions running them.
- A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia
E.r. Squibb & Sons, L.l.c. - A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderl…
Janssen Research & Development, LLC - A Randomized, Double-blind, Multicenter, Placebo-controlled, Proof-of-Concept Study to Evaluate the Efficacy, Safety, and Tolerability of JNJ-89495120 as Monotherapy in Adult Participants with Major Depressive Disorde…
Janssen Research & Development, LLC - ITI-007-452
Iti, Inc. (d/b/a Intra-cellular Therapies, Inc.) - A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD) (VENTURA-LT)
Janssen Research & Development, LLC - A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE)
E.r. Squibb & Sons, L.l.c. - A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar-I Disorder
E.r. Squibb & Sons, L.l.c. - A Randomized, Double-blind, Multicenter, Placebo-controlled Study to Evaluate the Efficacy, Safety and Tolerability of Aticaprant 10 mg and 5 mg as Adjunctive Therapy in Adult Participants with Major Depressive Disord…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.